Psychedelics.
Nichols DE.
Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E.
BMJ. 2023 Aug 30;382:e072348. doi: 10.1136/bmj-2022-072348.
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR.
JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285.
Human hallucinogen research: guidelines for safety.
Johnson M, Richards W, Griffiths R.
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis.
Myran DT, Harrison LD, Pugliese M, Solmi M, Anderson KK, Fiedorowicz JG, Perlman CM, Webber C, Finkelstein Y, Tanuseputro P.
JAMA Psychiatry. 2023 Nov 1;80(11):1169-1174. doi: 10.1001/jamapsychiatry.2023.3582.
The History of Psychedelics in Psychiatry.
Nichols DE, Walter H.
Pharmacopsychiatry. 2021 Jul;54(4):151-166. doi: 10.1055/a-1310-3990. Epub 2020 Dec 7.
Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis.
Murrie B, Lappin J, Large M, Sara G.
Schizophr Bull. 2020 Apr 10;46(3):505-516. doi: 10.1093/schbul/sbz102.
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
Hinkle JT, Graziosi M, Nayak SM, Yaden DB.
JAMA Psychiatry. 2024 Dec 1;81(12):1225-1235. doi: 10.1001/jamapsychiatry.2024.2546.
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W.
Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520.
New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects.
Taflaj B, La Maida N, Tittarelli R, Di Trana A, D'Acquarica I.
Int J Mol Sci. 2024 Aug 31;25(17):9484. doi: 10.3390/ijms25179484.
